Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Stock Has Consensus Target Price of $17.20 According to Brokerages

Shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $17.20.

SENS has been the subject of a number of analyst reports. Mizuho dropped their price target on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Wall Street Zen upgraded shares of Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised shares of Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th.

Insider Activity

In other news, Director Douglas Roeder acquired 13,953 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were acquired at an average cost of $8.98 per share, with a total value of $125,297.94. Following the completion of the purchase, the director directly owned 171,191 shares of the company’s stock, valued at $1,537,295.18. The trade was a 8.87% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the second quarter worth $15,867,000. Bank of America Corp DE acquired a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter valued at $2,241,000. Masters Capital Management LLC raised its position in Senseonics Holdings, Inc. Common Stock by 100.0% during the 1st quarter. Masters Capital Management LLC now owns 500,000 shares of the company’s stock worth $3,330,000 after purchasing an additional 250,002 shares during the last quarter. Readystate Asset Management LP bought a new position in Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth $574,000. Finally, Penn Capital Management Company LLC acquired a new position in Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth about $535,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Holdings, Inc. Common Stock Stock Performance

Shares of NASDAQ:SENS opened at $9.88 on Thursday. Senseonics Holdings, Inc. Common Stock has a 12-month low of $4.79 and a 12-month high of $11.58. The company’s 50 day moving average price is $8.44 and its two-hundred day moving average price is $7.00. The firm has a market cap of $412.98 million, a PE ratio of -4.43 and a beta of 1.02. The company has a quick ratio of 6.40, a current ratio of 6.74 and a debt-to-equity ratio of 0.62.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). The business had revenue of $14.48 million during the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%. Equities research analysts predict that Senseonics Holdings, Inc. Common Stock will post -2.31 earnings per share for the current year.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc is a medical technology company focused on developing and commercializing continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to measure glucose levels continuously and provide data through a wearable transmitter and mobile application, supporting diabetes management and treatment decisions.

The company’s primary product is the Eversense CGM system, which uses a small sensor implanted under the skin and a removable, rechargeable transmitter worn over the sensor.